论文部分内容阅读
目的探讨泼尼松联合尿激酶治疗结核性胸膜炎的临床疗效。方法选取2013年8月—2014年8月攀枝花市第四人民医院收治的结核性胸膜炎患者114例,按照随机数字表法将患者分成治疗组和对照组,各57例。两组患者均给予2HRS/4HR方案抗结核治疗,治疗组同时给予泼尼松联合尿激酶治疗,比较两组的吸收时间、抽液总量和胸膜厚度以及临床疗效。结果治疗组吸收时间长于对照组,抽液总量多于对照组,胸膜厚度小于对照组,总有效率高于对照组,差异有统计学意义(P<0.05)。结论泼尼松联合尿激酶治疗结核性胸膜炎的临床疗效显著,能够有效缓解患者症状。
Objective To investigate the clinical efficacy of prednisone combined with urokinase in the treatment of tuberculous pleurisy. Methods A total of 114 patients with tuberculous pleurisy were enrolled in the Fourth People’s Hospital of Panzhihua from August 2013 to August 2014. The patients were divided into treatment group and control group according to random number table method, 57 cases each. Two groups of patients were given 2HRS / 4HR program anti-TB treatment, the treatment group were treated with prednisone combined with urokinase, the absorption time of the two groups, the total amount of fluid pumping and pleural thickness and clinical efficacy. Results The absorption time of the treatment group was longer than that of the control group, and the total amount of fluid extraction was more than that of the control group. The pleural thickness was smaller than that of the control group, and the total effective rate was higher than that of the control group. The difference was statistically significant (P <0.05). Conclusions Prednisone combined with urokinase in the treatment of tuberculous pleurisy has a significant clinical effect and can effectively alleviate the symptoms of patients.